Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173778 · ClinicalTrials.gov registry record · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
A Phase 2 study of Obesity and Overweight, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
- 2
- Study locations
NCT06173778: Recruiting Phase 2 study of Obesity and Overweight, sponsored by The University of Texas Health Science Center, Houston.
NCT06173778 is a Phase 2 study of Obesity and Overweight that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 197 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06173778, a Phase 2 study of Obesity and Overweight, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG semaglutide 2.4mg
- DRUG Nicotine Replacement Therapy (NRT, nicotine patch)
- BEHAVIORAL Brief Smoking Cessation Counseling
Study Locations (2)
Texas
- The University of Texas at Austin - Austin
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2024-04-23 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 2 |
What NCT06173778 shows while recruiting
NCT06173778 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06173778 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06173778 about?
NCT06173778 is a clinical study titled "Semaglutide for Post-Smoking Cessation Weight Management". This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
What is the current status of trial NCT06173778?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2024-04-23. Estimated completion is 2026-08-01.
What conditions does trial NCT06173778 study?
This clinical trial studies the following conditions: Obesity, Overweight, Cigarette Smoking.
What interventions are being tested in trial NCT06173778?
The interventions under investigation include: Placebo (DRUG), semaglutide 2.4mg (DRUG), Nicotine Replacement Therapy (NRT, nicotine patch) (DRUG), Brief Smoking Cessation Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT06173778?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173778 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06173778's enrollment target sits among peer trials
197 325th of 1053 higher than 729 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI